BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

Free Newsletters
My Subscriptions

News by Subject
News by Disease
News by Date
Search News
Post Your News

Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Pharm Country
  Bio NC
  Southern Pharm
  BioCanada East
  C2C Services & Suppliers™


Company Profiles

Research Store

Research Events
Post an Event
Real Estate
Business Opportunities

By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search
 Company Profile


Idenix Pharmaceuticals, Inc. 

Corporate Headquarters
60 Hampshire Street
Cambridge  Massachusetts  02139  U.S.A.
Phone: 617-995-9800 Fax: 617-995-9801


View Clinical Trials from BioPharm Insight

Idenix Pharmaceuticals, Inc. is a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of human viral diseases. Idenix's current focus is on the treatment of infections caused by hepatitis C virus. Idenix is advancing a robust product pipeline in HCV treatment with programs in four different HCV drug classes. The company’s clinical candidates include IDX184, a liver-targeted nucleotide polymerase inhibitor, IDX320, a protease inhibitor and IDX375, a non-nucleoside polymerase inhibitor. Idenix also has a preclinical NS5A inhibitor program. Idenix believes that the future of HCV treatment will include novel combinations of direct-acting antivirals (DAAs) which could eliminate the need for interferon and/or ribavirin. The company’s goal is to develop low dose, once- or twice-daily agents with broad genotypic activity, a low potential for drug-drug interaction and that are designed for use in multiple combination regimens. With programs that span the major HCV drug classes, Idenix is well positioned to build a combination drug development strategy, both internally and with partners, to advance the future HCV paradigm.

 Key Statistics

Ownership: Public

Web Site: Idenix Pharmaceuticals, Inc.
Employees: 200 + worldwide
Symbol: IDIX

 Company News
Merck & Co., Inc. (MRK) Completes Tender Offer To Acquire Idenix Pharmaceuticals, Inc. (IDIX) 8/5/2014 10:19:26 AM
Idenix Pharmaceuticals, Inc. (IDIX) Reports Second Quarter And Six Month 2014 Financial Results 8/1/2014 10:19:37 AM
Merck & Co., Inc. (MRK) Begins Tender Offer To Acquire Idenix Pharmaceuticals, Inc. (IDIX) 6/20/2014 10:31:18 AM
Merck & Co., Inc. (MRK) Open To More Biotech Deals After Idenix Pharmaceuticals, Inc. (IDIX): Research Chief 6/13/2014 6:27:25 AM
AbbVie (ABBV) And Johnson & Johnson (JNJ) Were In A Bidding War For Idenix Pharmaceuticals, Inc. (IDIX), Will Achillion Pharmaceuticals, Inc. (ACHN) Be The Next Target? 6/12/2014 5:38:38 AM
Merck & Co., Inc. (MRK) Snags Cambridge's Idenix Pharmaceuticals, Inc. (IDIX) For $3.85 Billion 6/9/2014 6:29:10 AM
Idenix Pharmaceuticals, Inc. (IDIX) Reports First Quarter 2014 Financial Results And HCV Pipeline Review 5/1/2014 4:42:32 PM
Idenix Pharmaceuticals, Inc. (IDIX) To Present At Three Upcoming Healthcare Conferences 4/30/2014 9:45:48 AM
Idenix Pharmaceuticals, Inc. (IDIX)'s "Good" News Shows Hep C Drug Market Increasingly Murky For Investors 4/9/2014 6:05:01 AM
Idenix Pharmaceuticals, Inc. (IDIX) Announces Promising Clinical Data And Continued Progress In Nucleotide Prodrug Development Programs For The Treatment Of Hepatitis C 4/7/2014 9:29:00 AM